PLK1 Multi-Epitope Vaccine: Immunoinformatic Design and In Vitro Validation Data

Gayatri Munieswaran designed and validated a multi-epitope cancer vaccine targeting the Polo-like kinase 1 (PLK1) protein. The dataset, last updated in June 2026, contains results from an immunoinformatic pipeline including epitope screening, vaccine construction, molecular docking, and preliminary in vitro cell assays. The final optimized gene expression construct is reported to be 6,488 base pairs long.

Use Cases

• Training epitope prediction models based on the described screening of B-cell, CTL, and HTL epitopes.
• Benchmarking molecular docking and dynamics simulations using the reported binding affinity of -402.83 kcal/mol with the TLR4 receptor.
• Analyzing immune simulation outputs based on the described elevated levels of IFN-gamma and IL-2 production.
• Studying gene construct optimization for recombinant vaccines based on the 6,488 bps sequence length.

Strengths

• Includes preliminary in vitro validation results from SKBR3 cell line treatment, showing decreased PLK1 transcript levels.
• Reports specific binding energy metrics, such as a -402.83 kcal/mol affinity for the TLR4 receptor.
• Describes a multi-faceted validation pipeline covering epitope screening, structural modeling, and immune simulation.

Limitations

• Row count and column-level documentation are absent; field semantics must be inferred after download.
• The dataset is small at 63.7 KB, indicating limited scope.
• Freshness should be verified as the last update is dated in the future (2026-06-02).

Provenance

Source

figshare, author Gayatri Munieswaran

Collection Method

Immunoinformatic analysis and in vitro cell assays, as described in the methodology.

Freshness

Last updated 2026-06-02 05:42:00; freshness should be verified.